FYB

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal diseases, including diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranpoto, Uptera, and Ravegza names. The company's pipeline includes FYB202, a biosimilar candidate for Stelara used in the treatment of Psoriasis, Crohn's disease, and ulcerative colitis which has completed the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea that treats ophthalmology related diseases, including neovascular age-related macular degeneration that has completed Phase III clinical trials.